Track the Kailera Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). The latest transaction was reported on 22 April 2026 (C). Among the most active insiders: Bain Capital Life Sciences Investors, LLC. The full history is openly available.
14
Insider Decl.
0
Thresholds
€277m
5 ops.
Buy Volume
·
0 ops.
Sell Volume
49Σ signal
Buys €277m· Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1,562,500 shares@ US$16.00100.0% of flowCommon StockSEC:0001193125-26-164407:2
Ideal exit: 15 Jan 2027 (T+270)
14 of 14 declarations
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare genetic diseases. It emphasizes innovation in the field of genome editing-based treatments.